Animal trials proved efficacy of Covaxin, India’s Covid-19 vaccine candidate, says Bharat Biotech  | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Monday
October 02, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
MONDAY, OCTOBER 02, 2023
Animal trials proved efficacy of Covaxin, India’s Covid-19 vaccine candidate, says Bharat Biotech 

Coronavirus chronicle

Hindustan Times
12 September, 2020, 01:10 pm
Last modified: 12 September, 2020, 04:21 pm

Related News

  • India launches world’s 1st intranasal Covid vaccine
  • ‘Big boost’: Bharat Biotech’s nasal Covid-19 vaccine gets green light
  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • US to share Covid vaccine technology, Biden tells global summit

Animal trials proved efficacy of Covaxin, India’s Covid-19 vaccine candidate, says Bharat Biotech 

Animal trials proved efficacy of Covaxin, India’s Covid-19 vaccine candidate, says Bharat Biotech 

Hindustan Times
12 September, 2020, 01:10 pm
Last modified: 12 September, 2020, 04:21 pm
A man rides his motorbike past a parked bus of India's biotechnology company Bharat Biotech outside its office in Hyderabad, India July 3, 2020. REUTERS/Stringer
A man rides his motorbike past a parked bus of India's biotechnology company Bharat Biotech outside its office in Hyderabad, India July 3, 2020. REUTERS/Stringer

Animal trials of Bharat Biotech International Limited's Covid-19 vaccine candidate, Covaxin, have been successful and the results showed the shot's "remarkable immunogenicity and protective efficacy" in the Phase I clinical trials in India, the drugmaker has said.

Covaxin, developed by the Indian Council of Medical Research (ICMR) and Bharat Biotech, is being tested at 12 institutes across India. The Hyderabad-based firm said the data from the study on primates substantiate the immunogenicity of the vaccine candidate.

"Bharat Biotech proudly announces the animal study results of COVAXIN - These results demonstrate the protective efficacy in a live viral challenge model," Bharat Biotech tweeted on Friday.

Bharat Biotech has said in a release that it developed and assessed the protective efficacy and immunogenicity of an inactivated Sar-CoV-2 vaccine (BBV152) or Covaxin in rhesus macaques. Twenty macaques were divided into four groups of five animals each, it said.

India initiates first human trials of coronavirus vaccine

"One group was administered a placebo while three groups were immunised with three different vaccine candidates at 0 and 14 days. All the macaques were challenged with SARS-CoV-2 14 days after the second dose. The protective response was observed with increasing SARS-CoV-2 specific IgG and neutralising antibody titres from third week post-immunisation," the drug company said.

It added that viral clearance was observed from "bronchoalveolar lavage fluid, nasal swab, throat swab, and lung tissues at 7 days post-infection in the vaccinated groups."

"No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group which showed features of interstitial pneumonia and localisation of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry," it added.

"To summarize, the vaccine candidate was found to generate robust immune responses. Thus, preventing infection and disease in the primates upon high amounts of exposure to live SARS-CoV-2 virus," it added.

Bharat Biotech had received approval from the Central Drugs Standard Control Organisation to conduct the Phase-II trials earlier this month. It had announced in June that it successfully developed Covaxin in collaboration with ICMR and the National Institute of Virology (NIV).

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine candidate has been developed and manufactured in Bharat Biotech's high containment facility located in Genome Valley, Hyderabad.

Covaxin is one of the frontrunners in the race for a Covid-19 vaccine in India. It is an "inactivated" vaccine — it works by injecting doses of the virus that have been killed aiming to prompt the body to build antibodies against it without the virus posing a threat.

Each stage of a vaccine's clinical trial tests its safety and ability to develop an effective immune response. Phase 1 focuses on determining safety and dosage in a small group of healthy participants, while Phase 2 looks at the vaccine's effectiveness. Phase 3 looks into these aspects in a much larger population that would represent a wider demographic.

Top News

Bharat Biotech / Coronavirus Vaccine / animal trial / COVAXIN

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Big drops in remittance, exports make reserves struggle harsher
    Big drops in remittance, exports make reserves struggle harsher
  • Representational image. Photo: Collected
    Why Bangladesh’s reserves tumble, Sri Lanka’s improve
  • Sketch: TBS
    Stop financing budget deficit by printing money to check inflation, Sadiq Ahmed tells BB

MOST VIEWED

  • Paperfly aborts flight
    Paperfly aborts flight
  • Photo: TBS
    Habibur Rahman takes charge as 36th DMP commissioner
  • Some banks get more remittance. Is it for extra efforts, or higher dollar rates?
    Some banks get more remittance. Is it for extra efforts, or higher dollar rates?
  • How China's Belt and Road changing Bangladesh's  infrastructures
    How China's Belt and Road changing Bangladesh's infrastructures
  • Photo: TBS
    Dhaka traffic slowest in world: Study
  • US dollar banknotes are seen in this illustration taken on 10 March 2023. Photo: Reuters
    Remittance earnings in September lowest in 41 months

Related News

  • India launches world’s 1st intranasal Covid vaccine
  • ‘Big boost’: Bharat Biotech’s nasal Covid-19 vaccine gets green light
  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • US to share Covid vaccine technology, Biden tells global summit

Features

Illustration: Collected

Apology to a life forgotten to live

8h | Features
Photo: Kazi Ashraf Uddin

Coffee: More than a beverage, something of a beloved

10h | Features
The price back to the normal range is possible if the corporations who control the feed market reduce the feed and chick prices. Photo: Noor-A-Alam

Will eggs ever return to their 'normal' price?

13h | Features
Photo & Coffee Sketch: Touseful Isalm

A coffee conversation with Rumi

1d | Features

More Videos from TBS

Everything about the ICC Cricket World Cup 2023 stadiums: Part 1

Everything about the ICC Cricket World Cup 2023 stadiums: Part 1

5h | TBS SPORTS
Apple is bringing new software updates to prevent overheating

Apple is bringing new software updates to prevent overheating

7h | Tech Talk
A unique study cafe in the city

A unique study cafe in the city

6h | TBS Stories
Reserves are falling even as the dollar's share of global payments rises

Reserves are falling even as the dollar's share of global payments rises

9h | TBS Economy
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]